Navigation Links
Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2008 Financial Results on Wednesday, May 14, 2008 at 4:30 P.M. EST
Date:5/13/2008

TORONTO, May 13 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Wednesday, May 14, 2008 at 4:30 P.M. EST to discuss the Third Quarter fiscal 2008 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the conference call, please dial 1-800-732-6870 (North America), 1-212-231-2901 (International). A replay of the conference call will be available on Transition's website http://www.transitiontherapeutics.com for seven days following the call.

About Transition

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit http://www.transitiontherapeutics.com.

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials and potential efficacy of its products. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions.


'/>"/>
SOURCE Transition Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Retiring Nurses See Healthcare Advocacy as Second Career - Healthcare Liaison Workshop June 7-8 Shows Them How to Make Transition
2. Scientists identify gatekeepers of breast cancer transition to invasive disease
3. Healthcare Coalition Launches Enhanced Website Offering Tools and Materials to Improve Patient Care During Transitions of Care
4. Transition Therapeutics to Present at 2008 Morgan Stanley Global Healthcare Unplugged Conference
5. Transitioning patients with pediatric disease to adulthood
6. American Lung Association Offers Smoke-Free Transition Help to Businesses
7. Institute for Integrative Nutrition Provides Tips to Transition Bodies for Fall, Winter, Spring, Summer Eating
8. Transition Therapeutics to Present at Cowen & Company 28th Annual Healthcare Conference
9. APhA Announces Plans for Executive Leadership Transition
10. Jan Marini Skin Research Introduces Age Intervention(R) Transitions - a New Frontier in Skin Care
11. AUDIO from Medialink and Transitions: Understanding the Dangers of UV Rays
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... This ... laser diffraction analysis as a tool to characterize particle size distributions in the ... obtain improved results and novel scientific findings. It describes methods of optimized and ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, a ... new informational post on robotic hair transplantation. San Francisco residents may be confused ... Follicular Unit Transplantation (FUT) can sound similar. Either treatment can be used to ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... lab became the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der ... , ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements for ...
(Date:2/26/2017)... ARLINGTON, VA (PRWEB) , ... February 26, 2017 , ... ... Medicaid Managed Care Summit, February 27-28 at the Sheraton Pentagon City Hotel in Arlington, ... work with PerformCARE to use behavioral health analytics to improve Medicaid population health management. ...
(Date:2/24/2017)... ... February 24, 2017 , ... Houston dentist ... his office, Antoine Dental Center. Currently, patients can get single dental implants for ... but patients can learn more about these offers by contacting Antoine Dental Center. ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Israel and TAMPA, Fla. , Feb. ... emerging medical device company focused on developing cerebral ... applauds the members of the FDA,s Circulatory System ... their acknowledgement of the need for cerebral protection ... "The statements shared by this FDA panel ...
(Date:2/27/2017)... Feb. 27, 2017  Impax Laboratories, Inc. (NASDAQ: IPXL ) today ... Raymond James and Associates, 38 th ... 2017 in Orlando, FL. Cowen ... ET on March 7, 2017 in Boston, MA. ... 16, 2017 in Miami, FL. ...
(Date:2/27/2017)... 27, 2017  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and ... , M.D., Ph.D., as President and Chief Executive Officer (CEO) ... 2017. Dr. Craig succeeds Richard Love , interim President ... Board of Directors.  Dr. Craig has over 20 years of ... US and Europe . "On ...
Breaking Medicine Technology: